3 Medical Service Industry Stocks Set to Tackle Workforce Challenges

The Medical Services sector is being driven by digital-health and analytics tailwinds—Roots Analysis pegs the global healthcare analytics market at $56.64B in 2025 with a 22.7% CAGR through 2035, while U.S. digital health is forecast to grow from $92.08B in 2025 to $248.11B by 2034 (CAGR 11.6%). Workforce shortages remain a material headwind (Mercer projects a 100,000 shortfall by 2028; WHO cites an 11 million physician gap globally), lifting labor costs and sustaining demand for tech-enabled care models. Zacks notes the industry trades at a forward P/E of 16.9x (vs. S&P 23.3x), has lagged the S&P (6.8% vs. 19.3% one-year), and highlights three Zacks #2 (Buy) names—Medpace (MEDP, 2025 EPS growth est. 17.2%, revenue +18.7%), Enhabit (EHAB, 2025 EPS +161.9%), and Progyny (PGNY, 2025 EPS +9.8%)—as potential beneficiaries of these structural trends.

Analysis

Market structure: Scale winners are CROs (MEDP), analytics vendors and home-based care (EHAB, PGNY-adjacent services) because tech and payer consolidation shift pricing power to platform providers; labor-intensive hospitals and ad-hoc staffing agencies are natural losers as wage inflation compresses margins. The data points—healthcare analytics CAGR ~22.7% to 2035 and digital-health CAGR ~11.6%—signal durable demand for software/outsourcing while tightening clinician supply raises unit labor costs 3–6% annually near-term.

Risk assessment: Tail risks include sudden reimbursement cuts (Medicare/Medicaid), data-privacy/AI regulation fines, or a pharma R&D slowdown that would hit CRO revenues; these could dent earnings by >15% in 6–12 months. Immediate (days/weeks) risks center on earnings revisions and contract wins/losses; medium-term (3–12 months) on margin pressure from wages; long-term (1–5 years) favors tech-enabled scale players if regulatory regime stays neutral.

Trade implications: Direct plays: bias long MEDP and EHAB, use PGNY for targeted exposure to specialty benefits. Pair trade: long MEDP / short staffing provider AMN to express structural outsourcing vs. spot staffing weakness. Options: use 6–9 month call spreads on MEDP to limit premium; size 1–3% notional per position and stop-loss at -12%/take-profit at +25%.

Contrarian view: Consensus underestimates execution risk at smaller names and overestimates immediate margins for all scale players—industry F12M P/E 16.9 vs S&P 23.3 suggests the market has not fully priced AI-enabled upside. Watch for an inflection where easing labor shortages or reimbursement changes flip the thesis; historical analogue: post-EHR winners gained after multi-year integration, not immediately.

Key Decisions for Investors

• Establish a 2–3% long position in Medpace (MEDP) within the next 2 weeks; target 18–24% upside over 12 months based on high R&D outsourcing demand, set a hard stop-loss at -12% and reassess on quarterly guidance or a missed study backlog report.
• Build a 1.5–2% long position in Enhabit (EHAB) to capture home-health/hospice secular tailwinds; trim or stop if same-store revenue growth falls below +1% YoY or EBIT margin compresses >200 bps through two consecutive quarters.
• Initiate a small tactical 1% notional 6–9 month call spread on Progyny (PGNY) (buy ATM, sell +15% OTM) to gain leveraged, capped-upside exposure to fertility benefits adoption; close on >30% IV spike or if utilization growth <5% over two quarters.
• Execute a dollar-neutral pair trade: long MEDP / short AMN (staffing) sized 1:1 (1–2% net exposure) to play outsourcing share gains vs. spot staffing pressure; unwind if spread narrows >8% or if AMN reports margin recovery.
• Reduce exposure to pure-play staffing and small regional hospital equities by ~50% over the next month and redeploy proceeds into software-enabled medical services and investment-grade healthcare credit (buy 5–7 yr IG healthcare bonds as a hedge if high-yield spreads widen >150 bps).